(C) iStock Images / Mitochondria
(C) iStock Images / Mitochondria

Bacteria’s secret weapon revealed

Embargoed until: Publicly released:
Peer-reviewed: This work was reviewed and scrutinised by relevant independent experts.

Experimental study: At least one thing in the experiment was changed to see if it had an impact on the subjects (often people or animals) – eg: changing the amount of time mice spend on an exercise wheel to find out what impact it has on weight loss.

Animals: This is a study based on research on whole animals.

Monash Biomedicine Discovery Institute (BDI) scientists have discovered a previously unknown method used by bacteria to evade immune responses. The study, published in Nature Microbiology, points to potential new ways of countering bacterial infections, which are becoming increasingly resistant to antibiotics.

Journal/conference: Nature Microbiology

Link to research (DOI): 10.1038/s41564-020-0773-2

Organisation/s: Monash University

Funder: This study was supported by the Australian National Health and Medical Research Council, Australian Research Council and Monash University with the expertise from the Monash Proteomics facility, Micro Imaging and Animal Research Platform.

Media release

From: Monash University

Bacteria’s secret weapon revealed

Monash Biomedicine Discovery Institute (BDI) scientists have discovered a previously unknown method used by bacteria to evade immune responses.

The study, published in Nature Microbiology, points to potential new ways of countering bacterial infections, which are becoming increasingly resistant to antibiotics.

First author Dr Pankaj Deo said researchers in Dr Thomas Naderer’s laboratory took a different approach to understanding the process by which bacteria release toxins that disarm the ‘power-house’ mitochondria in immune cells.

The study showed that immune cells sense that their mitochondria are no longer functional during infections, which triggers apoptosis.  “Ironically, it is the activation of host cell death factors that deliver the final blow to mitochondria which induces apoptosis, not the bacterial toxins themselves,” Dr Pankaj said.

The researchers genetically targeted apoptotic factors and showed that they were able to reduce inflammation in mice, which increased health outcomes.

They used the bacterial pathogens Neisseria gonorrhoeae, uropathogenic Escherichia coli and the deadly Pseudomonas aeruginosa, prevalent in hospitals and which can be multi-drug resistant. However, the findings would apply to other species of bacteria too, Dr Deo said.

Dr Naderer, who oversaw the research, said that understanding the ways some bacterial infections evade immune response by targeting mitochondria opens new therapeutic possibilities.

“There’s been a lot of effort trying to block endotoxins that kill immune cells but this study really shifts the focus onto different toxins that might be more important,” Dr Naderer said.

“It gives us a few good leads that we can look at as a next step,” he said.

“We’ve shown in this paper that we can accelerate the immune response,” he said. “The other side is that if that response persists and we get constant inflammation – which is usually associated with bacterial infection and which causes a lot of tissue damage – we have a new way to shut down that tissue-damaging inflammation.”

“What scientists have thought before is that when endotoxins are released by bacteria they induce an inflammatory type of programmed cell death called pyroptosis in immune cells,” Dr Deo said. Endotoxins are part of the external cell wall of essentially all Gram-negative bacteria.

“We’ve found that the pathogenic bacteria use a similar mechanism to release additional toxins,” he said. “They kill immune cells by releasing small surface structures called outer membrane vesicles – packages of toxins that target mitochondria. The mitochondria are disarmed, become dysfunctional then die according to apoptosis or cellular suicide.”

The scientists will investigate drugs that are now advancing to the clinic, and at repurposing drugs already in use, perhaps as anti-cancer treatments, to see if they can be used to clear bacterial infections.

Collaborators included Dr Kate Lawlor from the Hudson Institute of Medical Research and Dr James Vince from the Walter and Eliza Hall Institute.

This study was supported by the Australian National Health and Medical Research Council, Australian Research Council and Monash University with the expertise from the Monash Proteomics facility, Micro Imaging and Animal Research Platform.

Read the full paper in Nature Microbiology titled: Mitochondrial dysfunction caused by outer membrane vesicles from Gram-negative bacteria activates intrinsic apoptosis and inflammation
DOI: 10.1038/s41564-020-0773-2

About the Monash Biomedicine Discovery Institute at Monash University
Committed to making the discoveries that will relieve the future burden of disease, the newly established Monash Biomedicine Discovery Institute at Monash University brings together more than 120 internationally-renowned research teams. Our researchers are supported by world-class technology and infrastructure, and partner with industry, clinicians and researchers internationally to enhance lives through discovery.

News for:

Australia
VIC

Media contact details for this story are only visible to registered journalists.